WO2000072021A3 - Cancer associated antigens and uses therefor - Google Patents

Cancer associated antigens and uses therefor Download PDF

Info

Publication number
WO2000072021A3
WO2000072021A3 PCT/US2000/014391 US0014391W WO0072021A3 WO 2000072021 A3 WO2000072021 A3 WO 2000072021A3 US 0014391 W US0014391 W US 0014391W WO 0072021 A3 WO0072021 A3 WO 0072021A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
associated antigens
cancer
cancer associated
peptides
Prior art date
Application number
PCT/US2000/014391
Other languages
French (fr)
Other versions
WO2000072021A2 (en
Inventor
Alexander Kuimov
Marka Lagarkova
Ekaterina Koroleva
Regina Turetskaya
Konstantin Vdovichenko
Andrei Mescheryakov
Mikhail Litchinitser
Dmitry Kuprash
Sergei Nedospasov
Ozlem Tureci
Ugur Sahin
Michael Pfruendschuh
Lloyd J Old
Alex Knuth
Elke Jager
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to AU51624/00A priority Critical patent/AU5162400A/en
Priority to EP00936286A priority patent/EP1208380A2/en
Priority to JP2000620358A priority patent/JP2003500072A/en
Publication of WO2000072021A2 publication Critical patent/WO2000072021A2/en
Publication of WO2000072021A3 publication Critical patent/WO2000072021A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Cancer associated antigens have been identified by autologous antibody screening of libraries of nucleic acids expressed in breast cancer and/or T cell leukemia cells using antisera from cancer patients. The invention relates to nucleic acids and encoded polypeptides which are cancer associated antigens expressed inpatients afflicted with cancer. The invention provides, inter alia, isolated nucleic acid molecules, expression vectors containing those molecules and host cells transfected with those molecules. The invention also provides isolated proteins and peptides, antibodies to those proteins and peptides and cytotoxic T lymphocytes which recognize the proteins and peptides. Fragments of the foregoing including functional fragments and variants also are provided. Kits containing the foregoing molecules additionally are provided. The molecules provided by the invention can be used in the diagnosis, monitoring, research, or treatment of conditions characterized by the expression of one or more cancer associated antigens.
PCT/US2000/014391 1999-05-26 2000-05-24 Cancer associated antigens and uses therefor WO2000072021A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU51624/00A AU5162400A (en) 1999-05-26 2000-05-24 Cancer associated antigens and uses therefor
EP00936286A EP1208380A2 (en) 1999-05-26 2000-05-24 Cancer associated antigens and uses therefor
JP2000620358A JP2003500072A (en) 1999-05-26 2000-05-24 Cancer-related drugs and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32009299A 1999-05-26 1999-05-26
US09/320,092 1999-05-26

Publications (2)

Publication Number Publication Date
WO2000072021A2 WO2000072021A2 (en) 2000-11-30
WO2000072021A3 true WO2000072021A3 (en) 2002-04-04

Family

ID=23244855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014391 WO2000072021A2 (en) 1999-05-26 2000-05-24 Cancer associated antigens and uses therefor

Country Status (4)

Country Link
EP (1) EP1208380A2 (en)
JP (1) JP2003500072A (en)
AU (1) AU5162400A (en)
WO (1) WO2000072021A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015647A1 (en) * 1997-09-23 1999-04-01 Garvan Institute Of Medical Research A potential effector for the grb7 family of signalling proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015647A1 (en) * 1997-09-23 1999-04-01 Garvan Institute Of Medical Research A potential effector for the grb7 family of signalling proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LYONS R J ET AL: "Identification of a novel human tankyrase through its interaction with the adaptor protein Grb14.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 20, 18 May 2001 (2001-05-18), pages 17172 - 17180, XP002177706 *
TÜRECI O ET AL: "Serological analysis of human tumor antigens: molecular definition and implications", MOLECULAR MEDICINE TODAY, vol. 3, no. 8, August 1997 (1997-08-01), pages 342 - 349, XP000985587 *

Also Published As

Publication number Publication date
WO2000072021A2 (en) 2000-11-30
AU5162400A (en) 2000-12-12
EP1208380A2 (en) 2002-05-29
JP2003500072A (en) 2003-01-07

Similar Documents

Publication Publication Date Title
WO2000073801A3 (en) Breast, gastric and prostate cancer associated antigens and uses therefor
WO2001053349A3 (en) Small cell lung cancer associated antigens and uses therefor
WO2000020587A3 (en) Cancer associated antigens and uses therefor
TW428026B (en) Bifunctional protein, preparation and use
WO1999066025A3 (en) Mtbx protein and nucleic acid molecules and uses therefor
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
AU6063500A (en) Glycoprotein vi and uses thereof
AU7599500A (en) Novel gl50 molecules and uses therefor
WO2002086071A3 (en) Cancer-testis antigens
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
WO2000052047A3 (en) Human dickkopf-related protein and nucleic acid molecules and uses therefor
WO2004024750A3 (en) Cd44-binding ligands
EP1009752A4 (en) Novel molecules of the tango-77 related protein family and uses thereof
WO2002078526A3 (en) Cancer-testis antigens
AU3217100A (en) Methods of use of a novel lysyl oxidase-related protein
AU626636B2 (en) Pancreatic islet cell antigens obtained by molecular cloning
AU6517400A (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO2000046236A3 (en) Novel rgs-containing molecules and uses thereof
WO2001025432A3 (en) Histamine receptor
WO2001000874A3 (en) Cancer associated antigens and uses therefor
WO2000072021A3 (en) Cancer associated antigens and uses therefor
WO2001040271A3 (en) Cancer associated antigens and uses therefor
WO2000020586A3 (en) Renal cancer associated antigens and uses therefor
WO2004003158A3 (en) Methods and compositions for modulating and detecting wisp activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 620358

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000936286

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWP Wipo information: published in national office

Ref document number: 2000936286

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000936286

Country of ref document: EP